|
1
|
Jia W, Wu J, Jia H, Yang Y, Zhang X, Chen
K and Su F: The peripheral blood neutrophil-to-lymphocyte ratio is
superior to the lymphocyte-to-monocyte ratio for predicting the
long-term survival of triple-negative breast cancer patients. PLoS
One. 10:e01430612015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ethier JL, Desautels D, Templeton A, Shah
PS and Amir E: Prognostic role of neutrophil-to-lymphocyte ratio in
breast cancer: A systematic review and meta-analysis. Breast Cancer
Res. 19:22017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu X, Qu JK, Zhang J, Yan Y, Zhao XX,
Wang JZ, Qu HY, Liu L, Wang JS and Duan XY: Prognostic role of
pretreatment neutrophil to lymphocyte ratio in breast cancer
patients: A meta-analysis. Medicine (Baltimore). 96:e81012017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Savas P, Salgado R, Denkert C, Sotiriou C,
Darcy PK, Smyth MJ and Loi S: Clinical relevance of host immunity
in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol.
13:228–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Landskron G, De la Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in
the tumor microenvironment. J Immunol Res. 2014:1491852014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Powell DR and Huttenlocher A: Neutrophils
in the tumor microenvironment. Trends Immunol. 37:41–52. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thrülimann B and Senn HJ: Panel members: Thresholds for
therapies: Highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang K, Xu J, Zhang T and Xue D:
Tumor-infiltrating lymphocytes in breast cancer predict the
response to chemotherapy and survival outcome: A meta-analysis.
Oncotarget. 7:44288–44298. 2016.PubMed/NCBI
|
|
9
|
Stanton SE and Disis ML: Clinical
significance of tumor-infiltrating lymphocytes in breast cancer. J
Immunother Cancer. 4:592016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwase T, Sangai T, Sakakibara M,
Sakakibara J, Ishigami E, Hayama S, Nakagawa A, Masuda T, Tabe S
and Nagashima T: An increased neutrophil-to-lymphocyte ratio
predicts poorer survival following recurrence for patients with
breast cancer. Mol Clin Oncol. 6:266–270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diehl A, Yarchoan M, Hopkins A, Jaffee E
and Grossman SA: Relationships between lymphocyte counts and
treatment-related toxicities and clinical responses in patients
with solid tumors treated with PD-1 checkpoint inhibitors.
Oncotarget. 8:114268–114280. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanizaki J, Haratani K, Hayashi H, Chiba
Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K,
et al: Peripheral blood biomarkers associated with clinical outcome
in non-small cell lung cancer patients treated with nivolumab. J
Thorac Oncol. 13:97–105. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goldhirsch A, Glick JH, Gelber RD, Coates
AS, Thürlimann B and Senn HJ: Panel members: Meeting highlights:
International expert consensus on the primary therapy of early
breast cancer 2005. Ann Oncol. 16:1569–1583. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goldhirsch A, Wood WC, Gelber RD, Coates
AS, Thürlimann B and Senn HJ: Progress and promise: Highlights of
the international expert consensus on the primary therapy of early
breast cancer 2007. Ann Oncol. 18:1133–1144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thrülimann B and Senn HJ: Panel members: Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members:
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen International Expert Consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel
Members: Tailoring therapies-improving the management of early
breast cancer: St Gallen International Expert Consensus on the
primary therapy of early breast cancer 2015. Ann Oncol.
26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawauchi S, Kono M, Takagi Y, Wada A and
Morikawa T: The positions of normal leukocytes on the scattergram
of the newly developed abnormal cell-detection channel of the
XN-series multi-parameter automated hematology analyzers. Sysmex J
Int. 23:1–9. 2013.
|
|
19
|
Dirican N, Karakaya YA, Gunes S, Daloglu
FT and Dirican A: Association of intra-tumoral tumour-infiltrating
lymphocytes and neutrophil-to-lymphocyte ratio is an independent
prognostic factor in non-small cell lung cancer. Clin Respir J.
11:789–796. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dirican A, Ekinci N, Avci A, Akyol M,
Alacacioglu A, Kucukzeybek Y, Somali I, Erten C, Demir L, Can A, et
al: The effects of hematological parameters and tumor-infiltrating
lymphocytes on prognosis in patients with gastric cancer. Cancer
Biomark. 13:11–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee J, Kim DM and Lee A: Prognostic role
and clinical association of tumor-infiltrating lymphocyte,
programmed death ligand-1 expression with neutrophil-lymphocyte
ratio in locally advanced triple-negative breast cancer. Cancer Res
Treat. doi:https://doi.org/10.4143/crt.2018.270.
|
|
22
|
Sacdalan DB, Lucero JA and Sacdalan DL:
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in
patients receiving immune checkpoint inhibitors: A review and
meta-analysis. Onco Targets Ther. 11:955–965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Houghton AM: The paradox of
tumor-associated neutrophils: Fueling tumor growth with cytotoxic
substances. Cell Cycle. 9:1732–1737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hurt B, Schulick R, Edil B, El Kasmi KC
and Barnett C Jr: Cancer-promoting mechanisms of tumor-associated
neutrophils. Am J Surg. 214:938–944. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uribe-Querol E and Rosales C: Neutrophils
in cancer: Two sides of the same coin. J Immunol Res.
2015:9836982015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Noh H, Eomm M and Han A: Usefulness of
pretreatment neutrophil to lymphocyte ratio in predicting
disease-specific survival in breast cancer patients. J Breast
Cancer. 16:55–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong
C, Su F and Song E: Pretreatment neutrophil-to-lymphocyte ratio is
correlated with response to neoadjuvant chemotherapy as an
independent prognostic indicator in breast cancer patients: A
retrospective study. BMC Cancer. 16:3202016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Asano Y, Kashiwagi S, Onoda N, Noda S,
Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K:
Predictive value of neutrophil/lymphocyte ratio for efficacy of
preoperative chemotherapy in triple-negative breast cancer. Ann
Surg Oncol. 23:1104–1110. 2016. View Article : Google Scholar : PubMed/NCBI
|
